Breaking News

Safety of accelerated schedules of allergen immunotherapy in atopic dermatitis

Safety of accelerated schedules of allergen immunotherapy in atopic dermatitis

 
 

The feasibility of administering house dust mite (HDM) extracts in 3 days (rush immunotherapy) or 1 day (ultra rush immunotherapy) to atopic dermatitis (AD) patients (n = 65) or allergic asthma patients (n = 19) was investigated. Systemic reactions (SRs) were seen in 29.4 and 31.3% of AD patients receiving rush and ultra-rush regimens, respectively. SRs were seen in 36.8% of allergic asthma patients receiving the rush regimen. Among the 20 AD patients showing SRs, 80% had urticaria, angioedema or a pruritic rash; 20% had a mild bronchospasm. No serious reactions or deaths were seen. Accelerated schedules may be a useful tool in the treatment of AD (Nahm, D-H. et ...

 
to Continue Reading, Login Now
 

Please Login

 
 
  
 
 
If you are a registered user but you have forgotten your password, please click here
 
If you are not a registered user, please register here

return to breaking news list